Association between Glucocorticoid Receptor Methylation and Hippocampal Subfields in Major Depressive Disorder

Kyoung-Sae Na1*, Hun Soo Chang2*, Eunsoo Won3, Kyu-Man Han3, Sunyoung Choi4, Woo Suk Tae5, Ho-Kyoung Yoon3, Yong-Ku Kim3, Sook-Haeng Joe3, In-Kwa Jung3, Min-Soo Lee3, Byung-Joo Ham3*

1 Department of Psychiatry, Gachon University Gil Medical Center, Incheon, Republic of Korea, 2 Department of Medical Bioscience, Graduate school, Soonchunhyang University, Bucheon, Republic of Korea, 3 Department of Psychiatry, College of Medicine, Korea University, Seoul, Republic of Korea, 4 Brain and Cognitive engineering, Korea University, Seoul, Republic of Korea, 5 Neuroscience Research Institute, College of Medicine, Kangwon National University, Chuncheon, Republic of Korea

Abstract

**Background:** DNA methylation in the promoter region of the glucocorticoid receptor gene (NR3C1) is closely associated with childhood adversity and suicide. However, few studies have examined NR3C1 methylation in relation to major depressive disorder (MDD) and hippocampal subfield volumes. We investigated the possible association between NR3C1 methylation and structural brain alterations in MDD in comparison with healthy controls.

**Methods:** We compared the degree of NR3C1 promoter methylation in the peripheral blood of non-psychotic outpatients with MDD and that of healthy controls. Correlations among NR3C1 promoter methylation, structural abnormalities in hippocampal subfield volumes and whole-brain cortical thickness, and clinical variables were also analyzed.

**Results:** In total, 117 participants (45 with MDD and 72 healthy controls) were recruited. Patients with MDD had significantly lower methylation than healthy controls at 2 CpG sites. In MDD, methylations had positive correlations with the bilateral cornu ammonis (CA) 2–3 and CA4-dentate gyrus (DG) subfields. However, in healthy controls, methylations had positive correlation with the subiculum and presubiculum. There were no differences in total and subfield volumes of the hippocampus between patients with MDD and healthy controls. Compared with healthy controls, patients with MDD had a significantly thinner cortex in the left rostromiddle frontal, right lateral orbitofrontal, and right pars triangularis areas.

**Conclusions:** Lower methylation in the NR3C1 promoter, which might have compensatory effects relating to CA2-3 and CA4-DG, is a distinct epigenetic characteristic in non-psychotic outpatients with MDD. Future studies with a longitudinal design and a comprehensive neurobiological approach are warranted in order to elucidate the effects of NR3C1 methylation.

Citation: Na K-S, Chang HS, Won E, Han K-M, Choi S, et al. (2014) Association between Glucocorticoid Receptor Methylation and Hippocampal Subfields in Major Depressive Disorder. PLoS ONE 9(1): e85425. doi:10.1371/journal.pone.0085425

Editor: Margaret M. DeAngelis, University of Utah, United States of America

Received July 18, 2013; Accepted November 26, 2013; Published January 21, 2014

Copyright: © 2014 Na et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2011-0023272). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: hambj@korea.ac.kr

These authors contributed equally to this work.

Introduction

Major depressive disorder (MDD) is one of the most common psychiatric illnesses [1]. According to the World Health organization (WHO), MDD is expected to be the second leading cause of disease burden by 2030 [2]. Given its increasing socioeconomic impact, numerous studies have investigated possible environmental and genetic factors contributing to MDD. Since MDD has a particularly low heritability rate (0.32) compared to schizophrenia (0.67) and bipolar disorder (0.62) [3], it is likely that gene-environment interactions play an important role in the development of MDD. Although a clear definition has not yet been established, epigenetics generally refers to (possibly heritable) changes in genetic activity without DNA sequence alterations through interactions with environmental factors [4].

The methylation at CpG sites in the promoter region of the glucocorticoid receptor gene NR3C1 is one of the most widely investigated epigenetic alterations in the field of psychiatry. Glucocorticoid secretion is a primary response to stress, and glucocorticoid receptor dysfunction accompanied by hypothalamic-pituitary-adrenal (HPA) axis hyperactivity has been hypothesized to be one of the major pathophysiologic alterations in MDD [5,6], although there are some inconsistencies [7,8]. Weaver et al. (2004) first reported that insufficient maternal licking and grooming in rats resulted in NR3C1 methylation in the promoter region exon 1, which corresponds to exon F1 in humans, and
adversely affected HPA axis response to stress [9]. Subsequent human studies have reported that prenatal risk factors or childhood adversity was associated with DNA methylation in the exon F1 region of the NR3C1 in the postmortem hippocampus of suicide victims [10–12]. The results suggest that higher methylation in NR3C1 in relation to early life adversities may also have causative roles for depression, which is closely related to suicide.

However, there have been no studies directly comparing NR3C1 methylation between patients with MDD and healthy controls. One of the previous studies measured NR3C1 methylation in patients with borderline personality disorder and MDD, but healthy controls were not included in the study [13]. The results showed that patients with borderline personality disorder, who had a significantly higher rate of childhood abuse, had significantly higher NR3C1 methylation than patients with MDD. Additionally, most epigenetic studies did not consider possible associations between epigenetic patterns and abnormalities in brain structure, particularly in the hippocampus, where most of the glucocorticoid receptors are located. Furthermore, the functions of the hippocampus vary according to subfields. For example, the dentate gyrus (DG), the cornu ammonis (CA) 3, and the CA4 (also referred to as hilus) are closely associated with treatment response in depression [14], whereas CA1 is the subfield most vulnerable to vascular injury [15]. On the other hand, glucocorticoid receptors are widely present in other brain regions such as the prefrontal cortex, amygdala, and hypothalamus [16,17]. Glucocorticoid receptors in the forebrain play an important role in depression [6,18]. Thus, structural analysis of the whole brain, as well as hippocampal subfield volume, should also be conducted to comprehensively identify neuroanatomical associations between NR3C1 methylation and MDD.

Given the above considerations, we hypothesized that patients with MDD would show higher NR3C1 methylation than healthy controls, which is consistently shown in studies investigating the association between methylation and childhood adversity. Subsequently, we further investigated the relationships between NR3C1 methylation and brain structural abnormalities in patients with MDD and healthy controls.

Methods and Materials

Ethics statement

All participants were provided with a full explanation of this study and gave written informed consent before enrollment in the study. The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Korea University Anam Hospital. This study was conducted in accordance with the Declaration of Helsinki as revised in 1989.

Participants

All subjects were aged 18 to 65 and recruited at Korea University Anam Hospital. Edinburgh Handedness Test [19] was applied to all participants before imaging acquisition to determine handedness. Since brain function and structures could be affected by handedness [20], only those who were right-handed were included in this study. Outpatients who were diagnosed with MDD were recruited. An Axis I diagnosis was determined by a board-certified psychiatrist, according to the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV) [21], using the Korean version of the Structured Clinical Interview for DSM-IV (SCID-IV) [Han, 2000]. Patients were excluded if they had: (1) a past or present history of comorbid axis I or II disorders according to DSM-IV criteria, (2) psychotic features (3) a history of taking antidepressants (4) an IQ score under 80, (5) a history of primary neurologic diseases, such as Parkinson’s disease and epilepsy, (6) organic brain lesions, such as cerebrovascular or space-occupying lesions, or (7) any contraindications for magnetic resonance imaging (MRI) such as pacemakers. Age- and sex-matched healthy controls who were confirmed to have no present, or past history of, psychiatric illnesses by board-certified psychiatrists were enrolled.

Severity of depression and perceived stress for all participants were measured on the day of MRI acquisition. Depression was measured by the 17-item Hamilton Rating Scale for Depression (HRSD) [22]. Perceived stress was evaluated by the perceived stress scale (PSS) [23], which consists of 14 5-point items. The PSS measures stress perceived by patients for the last month. Scores range from 0 to 40, and higher scores represent more stress. The reliability and validity has been established in Korean [24].

Selection of genomic regions of the NR3C1 gene for methylation analysis

We measured methylations at 5 CpG sites (CpG1 = −293, CpG2 = −286, CpG3 = −283, CpG4 = −277, and CpG5 = −274 in the 1F regions, distance (nt) from transcription start site (+1)) in accordance with previous studies [13,25].

DNA methylation analysis by pyrosequencing analysis

We used the bisulfite pyrosequencing method for methylation analyses of the NR3C1 promoter regions. Polymerase chain reaction (PCR) and sequencing primers were designed using Pyrosequencing Assay Design Software v2.0 (Qiagen; Valencia, CA, US). The primer sequence and target region are listed in Table 1 and Fig. S1 in File S1. Bisulfite-modified gDNA was prepared using EZ DNA Methylation-Gold kit (Zymo Research; Orange, CA, US), according to the manufacturer’s instructions. The bisulfite reaction was carried out on 500 ng gDNA, and the reaction volume was adjusted to 20 μl with sterile water, and 130 μl of CT conversion Reagent was added. The sample tubes were placed in a thermal cycler (MJ Research, Inc., Waltham, MA, US) and the following steps were performed: 10 min at 98°C, 2 h 30 min at 64°C, and stored at 4°C. The DNA was purified using reagent contained in EZ DNA Methylation-Gold kit (Zymo Research; Orange, CA, US). The converted samples were added into a Zymo-Spin ICTM Column containing 600 μl of the M-Binding Buffer and mixed by inverting the column several times. The column was centrifuged at full speed for 30 s and the flow-through was discarded. The column was washed by adding 200 μl of M-Wash Buffer and spun at full speed, and then 200 μl of M-Desulphonation Buffer was added to the column and was let stand at room temperature (20–30°C) for 15–20 min. After incubation, the column was centrifuged at full speed for 30 s. The column was washed by adding 200 μl of M-Wash Buffer and spun at full speed (this step was repeated). The converted gDNA was eluted by adding 20 μl of M-Elution Buffer into the column and spun. DNA samples were finally stored at −20°C until further use.

PCR was carried out in a volume of 20 μl with 20 ng or more of converted DNA, 2.5 μl of 10× Taq buffer, 5-unit Hot/Start Taq polymerase (Enzymatics; Daejeon, Korea), 2 μl of each 2.5 mM dNTP mixture, 1 μl of 10 pmole/μl Primer-S, and 1 μl of 10 pmole/μl biotinylated-Primer-As. The amplification was carried out according to the general guidelines suggested by Pyrosequencing; denaturing at 95°C for 10 min, followed by 45 cycles at 95°C for 30 s, at 55°C for 30 s, at 72°C for 30 s, and a final extension at 72°C for 5 min. The PCR (2 μl) was confirmed by electrophoresis in a 2% Agarose gel and visualized by ethidium bromide staining. ssDNA template was prepared from 16 to 18 μl.
biotinylated PCR product using streptavidin Sepharose® HP beads (Amersham Biosciences AB; Upsala, Sweden) following the PSQ 96 sample preparation guide using multichannel pipets. For analysis, 15 pmole of the respective sequencing primer was added. Sequencing was performed in a PyroMark ID system with the Pyro Gold reagents kit (Qiagen; Valencia, CA, US), according to the manufacturer’s instructions without further optimization. The degree of methylation at each CpG site was estimated using Pyro Q-CpGTM Software (Qiagen; Valencia, CA, US).

Statistical analysis

Hippocampal subfield volumes between patients with MDD and healthy controls were compared using analysis of covariance (ANCOVA) adjusted for age. To prevent inflated positive results (type I error), the significance level was set according to Bonferroni-corrected α values in the between-group analysis (p<0.01) when comparing methylation at 5 CpG sites.

Hippocampal subfield volumes and regional cortical thickness were imported into the SPSS 16.0 software (Chicago, IL, US) for statistical analysis. Relationships among hippocampal subfield volumes, methylation, and duration of illness were analyzed. In the case of cortical thickness, a vertex-wise general linear model, with controlling for age, sex, and total intracranial volume, was used to detect the following: 1) differences in cortical thickness between patients and controls, 2) correlation between CpG methylation and cortical thickness in patients with MDD and healthy controls. Age, sex, and total intracranial volume were included as covariates for all analyses regarding brain structures. Multiple comparisons correction was applied to between-group analyses in hippocampal subfield structures and cortical thickness. Regarding hippocampal subfield analysis, p<0.0036 (0.05/14) was applied. Regarding cortical thickness, Monte-Carlo permutation test implemented in FreeSurfer were applied, and the statistical significance level was considered at cluster-wise probability (CWP), which is similar to alpha significance, p<0.05. In the case of explorative correlation analyses among methylation, brain structures, and clinical variables, uncorrected p values (p<0.05) were applied.

Results

Participants

A total of 117 participants (45 with MDD and 72 healthy controls) were recruited. Demographic and clinical data for patients with MDD and healthy controls are presented in Table 2. There were no significant differences in age and sex between the 2 groups. Among the MDD group, 39 of 45 MDD patients had a mild to moderate degree of depression, whereas only nine (20%) patients were severely depressed [31].

Comparison of NR3C1 methylation and hippocampal subfield volumes between patients with MDD and healthy controls

Patients with MDD had significantly lower methylation at CpG 3 and CpG4 compared to healthy controls (Fig. 1, Table S1 in File S1). There were no significant differences in CpG sites 1, 2, and 5 between the 2 groups. There were no differences in hippocampal subfield volumes between patients with MDD and healthy controls (Fig. 2, Table S2 in File S1).

Table 1. Primers for bisulfite polymerase chain reaction and pyrosequencing.

| Genes | Primer (5’→3’) | Assayed CpG sites* | Annealing Tm | Amplicon size |
|-------|----------------|--------------------|--------------|--------------|
| NR3C1 | Forward        | GGAAGAGGCTAGAGGAAAGAAATTG | –293 | 55°C | 175 bp |
|       | Reverse        | Biotin- AACTCCCCAAAAAAAAATAAC | –283 | | |
|       | Sequencing (F) | TAAAGTAGTTTTAGAGAGATGG | –277 | | |
|       | Sequencing (R) | TTAAAGTAGTTTTAGAGAGATGG | –274 | | |

*Distance (nt) from transcription start site (+1).

doi:10.1371/journal.pone.0085425.t001

NR3C1 Methylation and Hippocampus in Depression
Comparisons of cortical thickness between patients with MDD and healthy controls

In the whole-brain analysis for cortical thickness between patients with MDD and healthy controls, the former had significantly thinner left rostromiddle frontal (Fig. 3), right lateral orbitofrontal (Fig. 4), and right pars triangularis cortices than healthy controls.

Correlations among NR3C1 methylation, brain structures, and clinical variables

In the MDD group, methylation at CpG1 had positive correlations with total, right total, and left total hippocampal volumes, as well as right CA1 and left CA1 (Fig. 5, Fig. 6, and Table S3 in File S1). Methylation at CpG3 and CpG4 had positive correlations with left CA2-3, left CA4-DG, and left hippocampal fissure volumes. Methylation at CpG2 and CpG5 had no correlations with hippocampal volumes. In healthy controls, there was no relationship between methylation and total hippocampal volume. Methylation at CpG2 had positive correlations with left fimbria volume. Methylation at CpG3 and CpG4 had positive correlations with left presubiculum and subiculum volumes. Methylation at CpG1, CpG2, and CpG5 had no correlations with hippocampal subfield volumes. Duration of illness was negatively correlated with right total hippocampal volumes, as well as right CA1, right CA2-3, right CA4-DG, right subiculum, and right fissure volumes. However, there were no relationships between duration of illness and left hippocampal volumes (Table S4 in File S1). Perceived stress had negative correlations with methylation at CpG3 in patients with MDD and CpG5 in healthy controls (Table S5 in File S1). Duration of illness was negatively correlated with methylation at CpG2 in patients with MDD.

In the whole-brain analysis for cortical thickness, duration of illness had positive associations with right isthmus ($r=0.442$, $p=0.004$) and right supramarginal ($r=0.351$, $p=0.024$) cortical thickness. In healthy controls, methylation at CpG1 had associations with the left pars orbitalis ($r=-0.318$, $p=0.008$) and left posterior cingulate cortex ($r=-0.288$, $p=0.016$). CpG4 was associated with the left fusiform cortex ($r=-0.242$, $p=0.045$). CpG5 had associations with the left rostomiddle frontal ($r=-0.261$, $p=0.031$) and right precentral cortex ($r=0.277$, $p=0.021$).

In patients with MDD, methylation at CpG1 was associated with the left entorhinal cortex ($r=0.327$, $p=0.037$). CpG2 was associated with the left frontal polar cortex ($r=0.331$, $p=0.034$). CpG3 was associated with the right pars triangular cortex ($r=-0.316$, $p=0.044$). CpG4 was associated with the left entorhinal cortex ($r=0.344$, $p=0.028$). CpG5 was associated with the left inferior parietal cortex ($r=-0.330$, $p=0.035$). There were no significant association between CpG5 methylation and cortical thickness in healthy controls.

Discussion

To the best of our knowledge, this is the first study to compare NR3C1 promoter region methylation between patients with MDD and healthy controls. We found a significant relationship between NR3C1 promoter methylation and hippocampal volumes in MDD patients. However, contrary to our hypothesis, our patients with MDD had significantly lower methylation at the CpG3 and CpG4 than healthy controls. There were no CpG sites in which methylation was increased in patients with MDD compared to healthy controls. Previous studies have reported that higher methylation may be related to repressed NR3C1 transcription, impaired glucocorticoid receptor function, and consequently HPA axis hyperactivity in MDD [9,11,25]. Also, as described in the introduction section, most of the previous studies focused on the relationship between NR3C1 methylation and early life adversities [12,13,32,33], rather than clinical status. When considering the subjects of these previous studies, higher methylation was found not only in clinical samples such as suicide victims [12] and borderline personality disorder patients [13], but also in healthy controls [33] and in a community-based general population [32]. Thus, there is a possibility that higher NR3C1 methylation found in these previous studies might represent a ‘scar’ of past childhood adversity, rather than current psychiatric vulnerability.

There were positive relationships between methylation and hippocampal subfield volumes in patients with MDD. NR3C1 methylation at CpG sites and increase in hippocampus subfield volumes were significantly associated in a greater number of regions, in patients with MDD compared to healthy controls. The degree of statistical significance was also greater in patients with

Table 2. Demographic and clinical data for patients with major depressive disorder and healthy controls.

|                        | MDD       | HC        | t or $\phi^2$ |
|------------------------|-----------|-----------|---------------|
| Age                    | 41.60 (11.80) | 40.72 (14.20) | 0.346         |
| Sex, female            | 34        | 51        | 0.311         |
| Education (years)      | 12.96 (2.80) | 13.84 (2.93) | -1.568        |
| Family history of MDD, yes* | 11       | 1         | 15.992        |
| HRSD scores*           | 19.84 (5.68) | 2.03 (2.23) | 20.10         |
| PSS scores*            | 18.13 (6.77) | 12.69 (8.47) | 3.83          |
| Duration of illness (months) | 29.78 (36.51) |

Number of past depressive episodes

| Number of episodes | MDD  | HC  | t or $\phi^2$ |
|-------------------|------|-----|---------------|
| 0                 | 24   | 53  |               |
| 1                 | 12   | 26  |               |
| 2                 | 4    | 8.9 |               |
| 3                 | 5    | 11.1|               |

All data are represented as mean (SD) or number (%). MDD: major depressive disorder, HC: healthy controls, HRSD: Hamilton Rating Scale for Depression, PSS: Perceived Stress Scale.

1*p<0.001.

doi:10.1371/journal.pone.0085425.t002

Figure 1. Comparison of NR3C1 methylation between patients with major depressive disorder and healthy controls, mean (SD). $p<0.01$.

doi:10.1371/journal.pone.0085425.g001
Figure 2. Comparison of hippocampal subfield volumes between patients with major depressive disorder and healthy controls, mean (SD).
doi:10.1371/journal.pone.0085425.g002

Figure 3. Differences in left cortical thickness between patients with major depressive disorder and healthy controls. FWE-corrected
p<0.05 through Monte-Carlo permutation test.
doi:10.1371/journal.pone.0085425.g003
MDD than in healthy controls. These results are not surprising, because glucocorticoid receptors are mainly involved in situations in which glucocorticoid levels are high, whereas mineralocorticoid receptors mediate glucocorticoid at a physiological level [34]. Methylation was particularly closely associated with CA2-3 and CA4-DG in patients with MDD. CA3, CA4, and DG are well known to be vulnerable to stress, thereby leading to depression and memory impairment [35–37]. DG and CA3 form neuronal circuitry mediated by mossy fibers, and are involved in synaptic and dendritic alterations under chronic stress, along with alterations in glucocorticoid activity [38,39].

Although glucocorticoid receptor resistance and impaired negative feedback loop of HPA hyperactivity is one of the major neuroendocrine alterations in MDD, the results have not been consistently replicated. Rather, HPA hyperactivity has been mainly found in psychotic depression [40] or severe depression [41]. A previous study reported that non-psychotic patients with MDD showed decreased 24 hour cortisol secretion, whereas psychotic patients with MDD had increased 24 hour cortisol secretion compared to healthy controls [7]. A recent study also reported that mild to moderate degree of depression may be associated with enhanced glucocorticoid receptor function and decreased HPA axis function [8]. In a meta-analysis, non-psychotic depressive patients had a 41% non-suppression for dexamethasone suppression test (DST) whereas psychotic patients had a 64% non-suppression [40]. One randomized controlled study even reported that intravenous hydrocortisone improved depressive symptoms [42]. Similar to the characteristics of depressive patients in the above studies, most of the patients in our study were diagnosed with mild to moderate depression. Thus, the higher NR3C1 methylation raises a possibility that methylation occurs in a compensatory pattern. However, given our study design and results, we could not determine whether the HPA axis was hypoactive in our MDD sample. Further studies should focus on the possible intrinsic mechanisms and effects of NR3C1 methylation in relation with HPA axis in MDD.

On the other hand, we could not find differences in hippocampal subfield volumes between patients with MDD and healthy controls. Whereas initial studies reported that chronic exposure to glucocorticoid could result in neuronal loss of the hippocampus [43], subsequent studies failed to consistently replicate the deleterious effects of glucocorticoid on the hippocampus [44,45]. Contrary to the non-significant differences in hippocampal volumes, in the whole brain analysis for cortical thickness, patients with MDD had significantly thinner left rostrormiddle frontal, right lateral orbitofrontal, and right pars triangularis cortex compared to healthy controls. These results are in accordance with a previous study reporting that orbitofrontal cortex was significantly thinner left rostrormiddle frontal, right lateral orbitofrontal, and right pars triangularis cortex compared to healthy controls [46], although no significant relationship between NR3C1 methylations and cortical thickness was reported.

Finally, although the significance level was relatively small, our findings of negative correlations between methylations and perceived stress supports the notion that methylation may occur to compensate the harmful alterations that are produced during
the course of depressive episodes. Whereas the environment and maternal care are main determinants for stress in animals and humans during the early childhood period, adulthood stress response is determined in the context of cognitive appraisal of individuals who perceive the stress [47,48]. Thus, it is worth to further investigate the causal relationship between adulthood perceived stress and epigenetic alterations.

There are several limitations that should be mentioned. First, we did not measure neuromolecular and biological factors that are possibly associated with the regulation and function of glucocorticoid receptors, which made it difficult to interpret neuromolecular mechanisms underlying associations between NR3C1 methylations and hippocampal subfield volumes. Second, we did not consider the childhood abuse history of participants, contrary to previous studies, since our main focus was to investigate whether the methylation in NR3C1 is different between patients with MDD and healthy controls. However, since we did not measure childhood adversities, we could not differentiate subgroups with childhood adversities. Our results, such as a lower NR3C1 methylation of patients with MDD and a positive correlation between NR3C1 methylation and hippocampal subfield volumes, might reflect clinical characteristics of MDD patients who do not have childhood adversities. Retrospective measures of childhood adversity are inevitably associated with recall bias. In addition, due to financial constraints and ethical issues, it is difficult to prospectively measure since childhood, the associations between childhood adversity and NR3C1 methylation, as well as HPA axis alterations. Finally, we measured NR3C1 methylation in peripheral blood, but not hippocampal tissues. Several studies have reported that methylation occurs in a tissue-specific manner [12,49]. Since DNA methylation is dependent on different brain regions, there is a possibility that our data represent NR3C1 distributed throughout various brain regions, and not confined to the hippocampus. However, previous studies reported that peripheral NR3C1 gene promoter methylation was associated with central glucocorticoid receptor mRNA expression [13,25]. Since peripheral factors representing the HPA axis, such as cortisol awakening response, could have a relationship with structural brain abnormalities including the hippocampus [50,51], NR3C1 methylation might also have correlations with hippocampal subfield volumes and cortical thickness. Additionally, considering its convenience for repeated measures and longitudinal follow-up, peripheral methylation has been recommended as a candidate method for measuring methylation in humans [52].

Despite the above limitations, our study has several clinical implications. First, to the best of our knowledge, this is the first study to compare NR3C1 gene methylation between patients with MDD and healthy controls. Second, by measuring hippocampal subfield and cortical thickness, we further comprehensively examined the association between methylation and structural brain abnormalities. Particularly, we strictly recruited drug-naive and non-psychotic patients with MDD to avoid possible confounding effects for methylation and structural brain abnormalities. Third, we used automated segmentation of hippocampal subfield volumes, which enabled us to measure hippocampal subfields with distinct functional characteristics. Specifically, regarding CA2-3 and CA4-DG subfields, the correlation coefficients with manual segmentation were 0.91 and 0.82, respectively [30].

Figure 5. Correlations between NR3C1 methylation at CpG1 and hippocampal subfield volumes among participants. doi:10.1371/journal.pone.0085425.g005
In conclusion, through this study, we raised critical issues regarding the role of NR3C1 methylation in patients with MDD as compared to healthy controls. Future studies with longitudinal designs and comprehensive measures of genetic and neurobiological factors related to NR3C1 methylation should be conducted in individuals with MDD.

Supporting Information

File S1  Table S1, Comparison of methylation between patients with major depressive disorder and healthy controls. Table S2, Mean hippocampal subfield volumes (measured in 0.5-mm³ voxels) between patients with major depressive disorder and healthy controls. Table S3, Partial coefficients between methylation and hippocampal subfield volumes among patients with major depressive disorder and healthy controls. Table S4, Correlations between methylation and clinical variables in participants with major depressive disorder and healthy controls. Figure S1, Schematic representation of NR3C1 promoter regions assessed by pyrosequencing.

Author Contributions
Conceived and designed the experiments: BJH. Performed the experiments: EW KMH SC. Analyzed the data: YKK SHJ IKJ MSL. Contributed reagents/materials/analysis tools: WST HKY. Wrote the manuscript: KSN HSC BJH.

References
1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617–627.
2. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
3. Wray NR, Gottesman II (2012) Using summary data from the danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder. Front Genet 3: 118.
4. Bogdano R, Hyde LW, Hariri AR (2013) A neurogenetics approach to understanding individual differences in brain, behavior, and risk for psychopathology. Mol Psychiatry 18: 288–299.
5. Marques AH, Silverman MN, Sternberg EM (2009) Glucocorticoid dysregulation and their clinical correlates. From receptors to therapeutics. Annu N Y Acad Sci 1179: 1–18.
6. Pariante CM, Miller AH (2001) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391–404.
7. Posner JA, DeBattista C, Williams GH, Chmura Kraemer H, Kaleyhsan BM, et al. (2000) 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiat 57: 755–760.
8. Krogh J, Videbæk P, Renvillard SG, Garde AH, Jorgensen MB, et al. (2012) Cognitive and HPA axis reactivity in mildly to moderately depressed outpatients: a case-control study. Nord J Psychiatry 66: 414–421.
9. Weaver IC, Cervoni N, Champagne FA, D’Alessio AC, Sharma S, et al. (2004) Epigenetic programming by maternal behavior. Nat Neurosci 7: 847–854.
10. Moser D, Molinor A, Kunsta R, Tatschner T, Riederer P, et al. (2007) The glucocorticoid receptor gene exon 1-F promoter is not methylated at the NGFI-A binding site in human hippocampus. World J Biol Psychiatry 8: 262–268.
11. McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonte B, et al. (2009) Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 12: 342–348.
12. Labonte B, Yerko V, Gross J, Mchawar N, Meaney MJ, et al. (2012) Differential glucocorticoid receptor exon 1(B), 1(C), and 1(H) expression and...
methylmethionine in suicide completers with a history of childhood abuse. Biol Psychiatry 72: 41–46.
13. Perroud N, Paoloni-Giacobino A, Prada P, Salzman A, et al. (2011) Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with a history of childhood maltreatment: a link with the severity and type of trauma. Transl Psychiatry 1: e59.
14. Russo-Neustadt AA, Aleksandrov A, Garcia C, Ivy AS, Chen M (2004) Hippocampal brain-derived neurotrophic factor expression following treatment with reboventine, citralopram, and physical exercise. Neuropsychopharmacology 29: 2189–2199.
15. He Z, He B, Behrle BI, Feijel MP, Cui L, et al. (2012) Ischaemia-induced increase in intracerebral phosphodiesterase 3D expression in rat hippocampus associated with blood brain barrier permeability: effect of age. ACS Chem Neurosci 3: 428–432.
16. Ahima RS, Harlan RE (1990) Charting of type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system. Neuroscience 40: 579–604.
17. Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, et al. (2000) Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res 34: 383–392.
18. Boyle MP, Brewster JH, Fanucci M, Wozniak DF, Tsien JZ, et al. (2005) Acquired deficit of forebrain glucocorticoid receptor produces depressionlike changes in adrenal axis regulation and behavior. Proc Natl Acad Sci U S A 102: 473–478.
19. Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9: 97–113.
20. Sun T, Walsh CA (2006) Molecular approaches to brain asymmetry and handedness. Nat Rev Neurosci 7: 655–662.
21. APA (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. Washington DC: American Psychiatric Association (APA).
22. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
23. Cohen S, Kamarck T, Mermelstein R (1983) A Global Measure of Perceived Stress. Journal of Health and Social Behavior 24: 385–396.
24. Park J, Sego YS (2010) Validation of the Perceived Stress Scale (PSS) on Samples of Korean University Students. Korean J Psychiatr 29: 611–629.
25. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Murti S, et al. (2008) Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 3: 97–106.
26. Dale AM, Fischer B, Sereno MI (1999) Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 9: 179–194.
27. Nakamura K, Fox R, Fisher E (2011) CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage 54: 278–289.
28. Fischer B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 97: 11050–11055.
29. Joshi V, Czaun S, Han X, Salat D, van der Kooi A, et al. (2001) MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 46: 177–192.
30. Van Leemput K, Bakhour A, Benner T, Wiggins G, Wald LL, et al. (2009) Automated segmentation of hippocampal subfields from ultra-high resolution in vivo MRI. Hippocampus 19: 549–557.
31. Cusin C, Yang H, Yeung A, Fava M (2011) Chapter 2. Rating Scales for Depression. In: Baxi I, Blain MA, editors. Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. NY: Humana Press.
32. Rakhe KM, Ruf M, Gunter HM, Dohrmann K, Schauer M, et al. (2011) Transgenerational impact of intimate partner violence on methylation in the promoter of the glucocorticoid receptor. Transl Psychiatry 1: e21.
33. Tyenka AR, Price LH, Marsit C, Walters OC, Carpenter LL (2012) Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: preliminary findings in healthy adults. PLoS One 7: e30148.
34. McEwen BS, Baran CA, Baran KW, Bullock K, Chambers WH, et al. (1997) The role of adrenoceptors as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Brain Res Rev 23: 79–133.
35. McEwen BS (2002) Sex, stress and the hippocampus: allostatics, allostatic load and the aging process. Neurobiol Aging 23: 921–939.
36. Huang Y, Coupland NJ, Lebel RM, Carter R, Sires P, et al. (2013) Structural Changes in Hippocampal Subfields in Major Depressive Disorder: A High-Field Magnetic Resonance Imaging Study. Biol Psychiatry.
37. Engvig A, Fjell AM, Westly TE, Skanne NV, Sundheth O, et al. (2012) Hippocampal subfield volumes correlate with memory training benefit in subjective memory impairment. Neuroimage 61: 181–194.
38. Kaest H, Joels M (2003) Effect of chronic stress on synaptic currents in rat hippocampal dentate gyrus neurons. J Neurophysiol 89: 625–633.
39. Paradis C, Nixon LG, McEwen BS (2002) Effects of chronic stress on hippocampal long-term potentiation. Hippocampus 12: 245–257.
40. Nelson JC, Davis JM (1997) DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 154: 1497–1503.
41. Jarurana MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, et al. (2006) Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl) 189: 225–235.
42. Watson S, Young AH (2001) Antidepressant effects of hydrocortisone. Am J Psychiatry 158: 1356–1357.
43. Landfield PW, Bashir RK, Pider TA (1981) Brain aging correlates: retardation by hormonal-pharmacological treatments. Science 214: 581–584.
44. Sousa N, Madeira MD, Paula-Barbosa MM (1998) Effects of corticosterone treatment and rehabilitation on the hippocampal formation of neonatal and adult rats. An unbiased stereological study. Brain Res 794: 199–210.
45. Tsai DA, Anderson BJ (2010) The effects of chronic glucocorticoid exposure on dendritic length, synapse numbers and glial volume in animal models: implications for hippocampal volume reductions in depression. Physiol Behav 99: 186–193.
46. Jarnum S, Ekdahl SF, Steffen ES, Lundby-Christensen S, Simonsen CW, et al. (2011) Longitudinal MRI study of cortical thickness, perfusion, and metabolite levels in major depressive disorder. Acta Psychiatr Scand 124: 435–446.
47. Lazarus RS (1992) Coping with the stress of illness. WHO Reg Publ Eur Ser 44: 11–31.
48. Dimsdale JE, Irwin M, Keefe FJ, Stein MB (2005) Stress and Psychiatry. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. PA., US: Lippincott Williams & Wilkins. pp. 2180–2195.
49. Liberman RA, Mashhood R, Thompson RC, Dolhoy DC, Champagne FA (2012) Concordance in hippocampal and feto NR3c1 methylation is moderated by maternal behavior in the mouse. Ecol Evol 2: 3123–3131.
50. Lu S, Gao W, Wei Z, Wu L, Liao M, et al. (2013) Reduced cingulate gyrus volume associated with enhanced cortisol awakening response in young healthy adults reporting childhood trauma. PLoS One 8: e69350.
51. Dedovic K, Engert V, Duchesne A, Lue SD, Andrews J, et al. (2010) Cortisol awakening response and hippocampal volume: vulnerability for major depressive disorder? Biol Psychiatry 68: 847–853.
52. Mill J, Petronis A (2007) Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry 12: 799–814.